Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry
Krish Patel(Sarah Cannon Research Institute), Bradley D. Hunter(Intermountain Healthcare), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Yi Lin(Mayo Clinic), David Bernasconi(Bristol-Myers Squibb (United States)), Iris Isufi(Yale University), Matthew J. Frigault(Harvard University), Minoo Battiwalla(Sarah Cannon), Marcelo C. Pasquini(Cleveland Clinic), Jennifer L. Crombie(Dana-Farber Cancer Institute), Matthew A. Lunning(University of Nebraska Medical Center), Uttam K. Rao(Sarah Cannon), Sami Ibrahimi(Oklahoma State University Oklahoma City), Debasmita Roy(Bristol-Myers Squibb (United States)), Konstantinos Sdrimas(West Virginia University)
Cited by 0
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|723
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560